Menu

Biosimilars

Biologicals 1 V13D05

Top 8 blockbuster biologicals 2013

Biosimilars/General | Posted 06/06/2014

The top three best-selling drugs during 2013 were biologicals. All three best-sellers are indicated for the treatment of arthritis, and include Abbott’s Humira (adalimumab), Merck’s Remicade (infliximab) and Roche’s Rituxan/MabThera (rituximab).

24 AA011041

Biosimilars developer Coherus raises US$55 million investment

Biosimilars/News | Posted 06/06/2014

US-based biosimilars developer Coherus BioSciences (Coherus) announced on 19 May 2014 that it had raised investments of US$55 million. New investors KKR & Co LP, Venrock, RA Capital Management, Rock Springs Capital and Fidelity Biosciences joined existing investors Sofinnova Ventures, Lilly Ventures and Vivo Capital.

Bevacizumab Avastin Roche V14e01

Biosimilars of bevacizumab

Biosimilars/General | Posted 02/06/2014

Last update: 5 February 2021

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.

11 AA010165

ABPI issues updated position paper on biosimilars

Biosimilars/General | Posted 02/06/2014

On 14 May 2014, the association that represents innovative research-based biopharmaceutical companies in the UK, the Association of the British Pharmaceutical Industry (ABPI), issued the third edition of its position paper on biosimilars.

Clinical Trials 2 V13K29

Pfizer to start phase III biosimilar trastuzumab trial

Biosimilars/News | Posted 02/06/2014

Pharma giant Pfizer is to start a global phase III trial for a biosimilar version of trastuzumab.

01 AA007239

Biosimilars on the horizon

Biosimilars/General | Posted 23/05/2014

Europe approved its first monoclonal antibody biosimilar, Inflectra/Remsima (infliximab), in September 2013 [1]. But how does the pipeline look for biosimilars and what will be the next biosimilar to be approved?

24 AA011041

Merck KGaA to invest Euros 100 million in biosimilars

Biosimilars/News | Posted 23/05/2014

Germany’s Merck KGaA is looking for new sources of growth, one of which it sees as being biosimilars.

picture 97

Synthon’s SYD985 outperforms Kadcyla in vitro and in vivo

Biosimilars/Research | Posted 23/05/2014

Synthon announced on 2 April 2014 that its antibody-drug conjugate SYD985 had outperformed Roche’s breast cancer blockbuster Kadcyla (trastuzumab emtansine) in a head-to-head comparison.

picture07

First biogeneric for Iran

Biosimilars/News | Posted 23/05/2014

Iran has developed the country’s first ‘biogeneric’ drug for cancer patients. The announcement was made in the presence of Iran’s Deputy Health Minister Hassan Hashemia at the beginning of February 2014, according to a report in the Tehran Times.

Quality, similarity and safety V13D12

Biosimilar epoetin shows good safety profile in post-authorization study

Biosimilars/Research | Posted 16/05/2014

US-based generics manufacturer Hospira announced on 28 April 2014 positive results from a post-authorization observational safety study of its biosimilar epoetin product Retacrit/Silapo (epoetin zeta) in patients with renal anaemia [1].